- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Biocardia Inc(BCDA)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BCDA
11/13/2026: BCDA (1-star) is currently NOT-A-BUY. Pass it for now.
BioCardia Inc. is a clinical-stage biotechnology company focused on developing proprietary catheter-based delivery systems and regenerative cell therapies for cardiovascular diseases. The company is characterized by its dual-track business model, seeking to control both the delivery platform and the therapeutic agent. Its main strengths lie in its specialized technology and a clear focus on addressing high-unmet-need heart conditions. However, the company faces significant risks, including the absence of commercial revenue, reliance on ongoing clinical trial success, and intense competition from much larger medical conglomerates. This stock is best suited for speculative investors comfortable with high volatility and long-term clinical trial risks who should monitor regulatory milestones closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers potential long-term growth through clinical success but carries significant early-stage risk. |
| Momentum investor | Weak fit | Momentum is often absent unless driven by major clinical catalysts or positive regulatory news. |
| Value investor | Weak fit | Valuation is difficult to determine based on standard metrics as the company lacks commercial revenue. |
| Dividend investor | Weak fit | BioCardia does not pay dividends and reinvests all capital into R&D. |
| Low-risk investor | Weak fit | High volatility and the risk of clinical trial failure make this unsuitable for risk-averse investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Small-cap biotech stocks frequently experience sharp price movements based on news cycles. |
| Valuation risk | High | Speculative valuation makes the stock sensitive to funding needs and clinical outcomes. |
| Competition risk (cardiovascular medical technology) | High | Large incumbents with greater resources may outcompete or render specific technologies obsolete. |
| Business quality | Medium | While the technology is innovative, the company remains in a developmental stage with no commercial revenue. |
| Dividend income | Low / none | There is no income component to this investment. |
| Execution risk | High | Success relies entirely on the execution of complex clinical trials and obtaining regulatory approval. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 12.58M USD | Price to earnings Ratio - | 1Y Target Price 15.5 |
Price to earnings Ratio - | 1Y Target Price 15.5 | ||
Volume (30-day avg) 122.5K shares | Beta 0.65 | 52 Weeks Range 0.66 - 1.50 | Updated Date 11/15/2026 |
52 Weeks Range 0.66 - 1.50 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.51 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Downtrend
The stock has experienced a sustained decline in price over recent periods.

Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -59.45% | Avg. Invested days 9 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Regenerative Therapeutics | Clinical-stage pipeline focusing on CardiAMP and CardiALLO therapies. | The company is an R&D venture currently spending money to prove its medical treatments work. |
| Cardiovascular Devices | Proprietary delivery catheters like the Helix system. | The company develops specialized tools to deliver advanced medicine directly to the heart. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 10.92M | Price to Sales(TTM) 2520.59 |
Enterprise Value 10.92M | Price to Sales(TTM) 2520.59 | ||
Enterprise Value to Revenue 23.81 | Enterprise Value to EBITDA -3.16 | Shares Outstanding 15.14M | Shares Floating 12.30M |
Shares Outstanding 15.14M | Shares Floating 12.30M | ||
Percent Insiders 18.82 | Percent Institutions 14.4 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

